<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/223248</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Epidemiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Circulating selenium and prostate cancer risk: a Mendelian randomization analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yarmolinsky</surname>
<given-names>James</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bonilla</surname>
<given-names>Carolina</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haycock</surname>
<given-names>Philip C</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Langdon</surname>
<given-names>Ryan JQ</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lotta</surname>
<given-names>Luca A</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Langenberg</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Relton</surname>
<given-names>Caroline L</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lewis</surname>
<given-names>Sarah J</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Evans</surname>
<given-names>David M</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<collab>the PRACTICAL consortium</collab>
<xref ref-type="author-notes" rid="n1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>George Davey</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Martin</surname>
<given-names>Richard M</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<aff id="a1"><label>1</label><institution>MRC Integrative Epidemiology Unit, University of Bristol</institution>, Bristol, <country>UK</country></aff>
<aff id="a2"><label>2</label><institution>Population Health Sciences, Bristol Medical School, University of Bristol</institution>, Bristol, <country>UK</country></aff>
<aff id="a3"><label>3</label><institution>MRC Epidemiology Unit, University of Cambridge</institution>, Cambridge, <country>UK</country></aff>
<aff id="a4"><label>4</label><institution>University of Queensland Diamantina Institute, Translational Research Institute</institution>, Brisbane, <country>Australia</country></aff>
<aff id="a5"><label>5</label><institution>University Hospitals Bristol NHS Foundation Trust National Institute for Health Research Bristol Nutrition Biomedical Research Unit, University of Bristol</institution>, Bristol, <country>UK</country></aff>
</contrib-group>
<author-notes>
<corresp>Corresponding author: Professor Martin, BMBS, PhD Population Health Sciences Bristol Medical School University of Bristol Canynge Hall, 39 Whatley Road Bristol BS8 2PS, United Kingdom Fax: &#x002B;44 117 928 7236 Tel: &#x002B;44 117 928 7321 ri <email>chard.martin@bristol.ac.uk</email></corresp>
<fn id="n1" fn-type="supplementary-material"><label>&#x002A;</label><p>Members from the PRACTICAL Consortium (<ext-link ext-link-type="uri" xlink:href="http://practical.ccge.medschl.cam.ac.uk/">http://practical.ccge.medschl.cam.ac.uk/</ext-link>) are provided in the Supplementary Materials.</p></fn>
</author-notes>
<pub-date pub-type="epub"><year>2017</year></pub-date>
<elocation-id>223248</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>21</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2017, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="223248.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 &#x03BC;g/L increase in circulating selenium) did not lower overall prostate cancer risk, but increased risk of high-grade prostate cancer and type 2 diabetes. Mendelian randomization analysis uses genetic variants to proxy modifiable risk factors and can strengthen causal inference in observational studies. We constructed a genetic risk score comprising eleven single-nucleotide polymorphisms robustly (<italic>P</italic>&#x003C;5x10<sup>&#x2212;8</sup>) associated with circulating selenium in genome-wide association studies. In a Mendelian randomization analysis of 72,729 men in the PRACTICAL Consortium (44,825 cases, 27,904 controls), 114 &#x03BC;g/L higher genetically-elevated circulating selenium was not associated with prostate cancer (OR: 1.01; 95&#x0025; CI: 0.89-1.13). Concordant with findings from SELECT, selenium was weakly associated with advanced (including high-grade) prostate cancer (OR: 1.21; 95&#x0025; CI: 0.98-1.49) and type 2 diabetes (OR: 1.18; 95&#x0025; CI: 0.97-1.43; in a type 2 diabetes GWAS meta-analysis with up to 49,266 cases, 249,906 controls). Mendelian randomization mirrored the outcome of selenium supplementation in SELECT and may offer an approach for the prioritization of interventions for follow-up in large-scale randomized controlled trials.</p>
</abstract>
<counts>
<page-count count="17"/>
</counts>
</article-meta>
</front>
<body>
<p>The development of interventions to prevent cancer requires robust causal knowledge, but few observational epidemiological claims are replicated in randomized controlled trials (RCTs) and some trial results are in the opposite direction to those seen observationally (i.e. causing harm) (<xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref>). Such failures to translate observational data into effective cancer prevention interventions arise in part because the inherent limitations of observational research - confounding, reverse causation, and measurement error - preclude confident causal inference.</p>
<p>Mendelian randomization uses genetic variants as instruments (i.e. proxies) to assess whether a potential intervention target (e.g. risk factor, molecular intermediate, or gene product) has a causal effect on a disease outcome in a non-experimental (observational) setting (<xref ref-type="bibr" rid="c3">3</xref>). The principle of Mendelian randomization is that analysis of groups defined by common genetic variants is analogous to that of intention-to-treat analysis in an RCT. This is based on the independent assortment of genetic variants at meiosis which should allow for genotype at a population level to be largely independent of later environment and lifestyle factors (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Using genetic variants as instruments to proxy intervention targets means that analyses should be less susceptible to confounding by environmental factors that typically distort observational associations. Furthermore, genotypes are typically measured with little error, represent life-long exposure, and are not subject to reverse causation because disease status cannot influence one&#x2019;s germline genotype.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Schematic comparison of a Randomized Controlled Trial (SELECT) to a Mendelian randomization analysis.</title><p>In an RCT, individuals are randomly allocated to an intervention or control group (In SELECT, 200 &#x03BC;g/d selenium [114&#x03BC;g/L increase in blood selenium] or placebo). If the trial is adequately sized, randomization should ensure that intervention and control groups are comparable in all respects (e.g. approximately equal distribution of potential confounding factors) except for the intervention being tested. In an intention-to-treat analysis, any observed differences in outcomes between intervention and control groups can then be attributed to the trial arm to which they were allocated. In a Mendelian randomization (MR) analysis, alleles that influence levels of a trait of interest are randomly allocated at conception (In MR, the additive effects of selenium-raising alleles at eleven SNPs were scaled to mirror a 114&#x03BC;g/L increase in blood selenium). Groups defined by genotype should be comparable in all respects (e.g. distribution of both genetic and environmental confounding factors) except for their exposure to a trait of interest. Any observed differences in outcomes between groups defined by genotype can then be attributed to differences in life-long exposure to the trait of interest under study.</p>
<p>Mendelian randomization is an application of the technique of instrumental variable (IV) analysis. In order for a genetic variant (or a multi-allelic genetic risk score) to be used as an IV, three key assumptions must be met: 1) The instrument must be reliably associated with the exposure of interest, 2) the instrument should be independent of other factors affecting the outcome (confounders), 3) the instrument should only affect the outcome through the exposure of interest (known as the exclusion restriction criterion).</p></caption>
<graphic xlink:href="223248_fig1.tif"/>
</fig>
<p>An advantage of Mendelian randomization is that implementation does not require access to individual level data or trait measurements in all samples: it can be implemented using information on genetic variant-exposure and genetic variant-outcome associations obtained from separate samples, which greatly increases the scope of the approach (&#x201C;two-sample Mendelian randomization&#x201D;) (<xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c5">5</xref>). Two-sample approaches using summary data can be used in an efficient and cost-effective manner to screen hundreds of potential intervention targets for causal relationships with cancer, without having to expensively measure these targets within individual cancer collections, and is made increasingly possible by the rapid increase in genome-wide association studies (GWAS) over the last decade; there are currently over 2000 published GWAS for over 1500 unique traits (<ext-link ext-link-type="uri" xlink:href="https://www.genome.gov/gwastudies/">https://www.genome.gov/gwastudies/</ext-link>).</p>
<p>The largest ever prostate cancer prevention trial (SELECT, N&#x003D;35,533) was designed to examine whether daily supplementation with selenium, vitamin E, or both agents combined, could prevent prostate cancer (<xref ref-type="bibr" rid="c6">6</xref>). It was abandoned at a cost of &#x0024;114 million because of lack of efficacy compounded by possible carcinogenic (increased rates of high-grade [Gleason score 7] prostate cancer) and adverse metabolic effects (increased rates of diabetes) of the interventions (<xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c7">7</xref>). We investigated whether Mendelian randomization could have predicted the results of the SELECT trial observed for selenium in a two-sample Mendelian randomization study of 72,729 individuals of European descent from the PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) consortium (<xref ref-type="bibr" rid="c8">8</xref>).</p>
<p>We obtained summary GWAS statistics from analyses on 44,825 prostate cancer cases and 27,904 controls of European descent from 108 studies in PRACTICAL. Summary statistics were also obtained from analyses on 6,263 advanced prostate cancer cases (defined as Gleason &#x2265;8, prostate-specific antigen &#x003E;100 ng/mL, metastatic disease (M1), or death from prostate cancer) and 27,235 controls (summary data on high-grade prostate cancer alone was not available). All studies in PRACTICAL have the relevant Institutional Review Board approval from each country, in accordance with the Declaration of Helsinki. Genotyping of PRACTICAL samples was performed using an Illumina Custom Infinium genotyping array (OncoArray), designed for the OncoArray consortium and consisting of &#x007E;570,000 single nucleotide polymorphisms (SNPs) (<xref ref-type="bibr" rid="c9">9</xref>). All SNPs with a poor imputation quality (r<sup>2</sup>&#x003C;0.30), a minor allele frequency of &#x003C;1&#x0025;, a call rate of &#x003C;98&#x0025;, or evidence of violation of Hardy-Weinberg equilibrium (<italic>P</italic>&#x003C;10<sup>&#x2212;7</sup> in controls or <italic>P</italic>&#x003C;10<sup>&#x2212;12</sup> in cases) were removed.</p>
<p>To analyze the effect of selenium on type 2 diabetes we used summary GWAS data from analyses in up to 49,266 type 2 diabetes cases and 249,906 controls of European descent obtained from a meta-analysis of the DIAbetes Genetics Replication And Meta-analysis (<xref ref-type="bibr" rid="c10">10</xref>), EPIC-InterAct (<xref ref-type="bibr" rid="c11">11</xref>), and UK Biobank studies (<xref ref-type="bibr" rid="c12">12</xref>). Methods for this meta-analysis have been published previously (<xref ref-type="bibr" rid="c13">13</xref>).</p>
<p>A genetic risk score to proxy for circulating selenium levels was constructed by obtaining SNPs shown to robustly (<italic>P</italic>&#x003C;5x10<sup>&#x2212;8</sup>) associate with selenium concentrations in a meta-analysis of blood and toenail selenium GWAS (<xref ref-type="bibr" rid="c14">14</xref>, <xref ref-type="bibr" rid="c15">15</xref>). Of twelve selenium SNPs identified, one (rs558133) was not available in PRACTICAL and thus eleven SNPs were used as genetic instruments for overall and advanced prostate cancer analyses. As sensitivity analyses, we also constructed a restricted genetic risk score using only SNPs robustly (<italic>P</italic>&#x003C;5x10<sup>&#x2212;8</sup>) associated with selenium in a GWAS of blood selenium that were replicated (<italic>P</italic>&#x003C;0.05) in subsequent independent studies (<xref ref-type="bibr" rid="c14">14</xref>&#x2013;<xref ref-type="bibr" rid="c16">16</xref>). For these analyses, of five selenium SNPs initially identified, one (rs6859667) was not available in PRACTICAL and thus four SNPs were used as instruments for both prostate cancer analyses. All SNPs utilised for primary and sensitivity analyses and their corresponding ENSEMBL-mapped gene(s) (<xref ref-type="bibr" rid="c17">17</xref>) are presented in the footnote to <xref ref-type="table" rid="tbl1">Table 1</xref>.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><p>Comparison of the effect of 114 ug/L selenium on overall prostate cancer, high-grade / advanced prostate cancer, and type 2 diabetes in SELECT and Mendelian randomization</p></caption>
<graphic xlink:href="223248_tbl1.tif"/>
</table-wrap>
<p>We constructed a correlation matrix to estimate correlation between SNPs with reference to the HapMap 3 (release 2) dataset. The causal effect of our genetic risk score on overall prostate cancer, advanced prostate cancer, and type 2 diabetes was then examined using a maximum likelihood approach that takes into account moderate correlations between genetic variants (<xref ref-type="bibr" rid="c18">18</xref>). To compare the causal odds ratios from Mendelian randomization with the hazard ratios from SELECT, we estimated the causal odds ratios per 114&#x03BC;g/L genetically increased circulating selenium, to match the measured preversus post-intervention blood selenium differences between supplementation and control arms in SELECT (<xref ref-type="bibr" rid="c6">6</xref>). All statistical analyses were performed using R version 3.0.2.</p>
<p>In Mendelian randomization analyses, a 114&#x03BC;g/L increase in genetically-elevated blood selenium was not associated with overall prostate cancer risk (OR: 1.01, 95&#x0025; CI: 0.89&#x2013;1.13, <italic>P</italic>&#x003D;0.93) (<xref ref-type="table" rid="tbl1">Table 1</xref>). Genetically elevated selenium was weakly associated with advanced prostate cancer (OR: 1.21, 95&#x0025; CI: 0.98-1.49, <italic>P</italic>&#x003D;0.07) and type 2 diabetes (OR: 1.18, 95&#x0025; CI: 0.97-1.43, <italic>P</italic>&#x003D;0.11). Results for overall prostate cancer, advanced prostate cancer and type 2 diabetes were robust to sensitivity analyses employing a restricted genetic risk score (ORs were 0.95 [95&#x0025; CI 0.80-1.14], 1.09 [0.81-1.47] and 1.23 [0.99-1.53]), respectively).</p>
<p>Limitations of our analysis include that we were only able to directly examine the effect of genetically elevated selenium on advanced prostate cancer and not high-grade prostate cancer per se (summary estimates from PRACTICAL were available only for a composite &#x201C;advanced&#x201D; disease classification), thus preventing direct comparison to results with SELECT. Additionally, our selenium SNPs were also associated with betaine, a putative risk factor for type 2 diabetes (<xref ref-type="bibr" rid="c19">19</xref>), which could introduce horizontal pleiotropy (genetic variants influencing an outcome through a different biological pathway from the exposure under investigation) into our analyses and thus invalidate instrumental variable assumptions (see footnote of <xref ref-type="fig" rid="fig1">Figure 1</xref>). Though we suspect that the association of these SNPs with both selenium and betaine reflects the effect of selenium on betaine in the methionine cycle (<xref ref-type="bibr" rid="c20">20</xref>, <xref ref-type="bibr" rid="c21">21</xref>) and, consequently, that both selenium and betaine likely influence type 2 diabetes risk through the same biological pathway, we cannot rule out the possibility that at least part of a putative effect of selenium SNPs on type 2 diabetes risk is through an alternate biological pathway involving betaine.</p>
<p>We conclude that in contrast to findings from some (<xref ref-type="bibr" rid="c22">22</xref>&#x2013;<xref ref-type="bibr" rid="c27">27</xref>) but not all prospective epidemiological studies (<xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c29">29</xref>), our Mendelian randomization analysis using publicly available GWAS data did not find strong evidence for a causal effect of selenium on overall prostate cancer. Consistent with SELECT, we found weak evidence of a positive effect of genetically elevated selenium on advanced prostate cancer. In agreement with SELECT, we also found weak evidence of a positive effect of genetically elevated selenium on type 2 diabetes risk. The alignment of Mendelian randomization with SELECT estimates mirrors the concordance of Mendelian randomization findings with other large, phase III trials; including adverse effects of elevated LDL cholesterol on coronary heart disease (<xref ref-type="bibr" rid="c30">30</xref>, <xref ref-type="bibr" rid="c31">31</xref>) and statin use with type 2 diabetes (<xref ref-type="bibr" rid="c32">32</xref>, <xref ref-type="bibr" rid="c33">33</xref>); and null effects of secretory phospholipase A(2)-IIA with cardiovascular disease (<xref ref-type="bibr" rid="c34">34</xref>&#x2013;<xref ref-type="bibr" rid="c36">36</xref>) and HDL cholesterol on risk of myocardial infarction (<xref ref-type="bibr" rid="c37">37</xref>&#x2013;<xref ref-type="bibr" rid="c40">40</xref>). Mendelian randomization may serve as an important time-efficient and inexpensive first step in predicting both the efficacy and possible adverse effects of an intervention prior to the design of a randomized controlled trial.</p>
<sec id="s1">
<title>Abbreviations</title>
<p>Randomized controlled trial (RCT), genome-wide association study (GWAS), Selenium and Vitamin E Cancer Prevention Trial (SELECT), Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL), single nucleotide polymorphisms (SNPs)</p>
</sec>
<sec id="s2" sec-type="funding">
<title>Funding</title>
<p>This work was supported by a Cancer Research UK programme grant (C18281/A19169), Cancer Research UK Research PhD studentships (C18281/A20988 to J.Y. and R.J.Q.L.), and a Cancer Research UK Population Research Postdoctoral Fellowship (C52724/A20138 to P.C.H.). This work was also supported by a grant awarded to S.J.L. for 3 years to identify modifiable risk factors for prostate cancer, by the World Cancer Research Fund International (grant reference number: 2015/1421). The Medical Research Council Integrative Epidemiology Unit at the University of Bristol is supported by the Medical Research Council (MC&#x005F;UU&#x005F;12013/1, MC&#x005F;UU&#x005F;12013/2, and MC&#x005F;UU&#x005F;12013/3) and the University of Bristol.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We are grateful to the contribution of data from EPIC-InterAct Investigators. The InterAct Study is led by Professor Nick Wareham at the MRC Epidemiology Unit, Cambridge, UK; InterAct funding was provided by the EU FP6 programme (grant number LSHM&#x005F;CT&#x005F;2006&#x005F;03 7197).</p>
</ack>
<ref-list>
<title>Citations</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Wiseman</surname> <given-names>M</given-names></string-name>. <article-title>The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective</article-title>. <source>Proc Nutr Soc.</source> <year>2008</year>;<volume>67</volume>(<issue>3</issue>):<fpage>253</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Ioannidis</surname> <given-names>JP</given-names></string-name>. <article-title>Implausible results in human nutrition research</article-title>. <source>BMJ</source>. <year>2013</year>;<volume>347</volume>:<fpage>f6698</fpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Smith</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Ebrahim</surname> <given-names>S</given-names></string-name>. <article-title>&#x2018;Mendelian randomization&#x2019;: can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title> <source>Int J Epidemiol.</source> <year>2003</year>;<volume>32</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>22</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Pierce</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Burgess</surname> <given-names>S</given-names></string-name>. <article-title>Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators</article-title>. <source>Am J Epidemiol.</source> <year>2013</year>;<volume>178</volume>(<issue>7</issue>):<fpage>1177</fpage>&#x2013;<lpage>84</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Burgess</surname> <given-names>S</given-names></string-name>, <string-name><surname>Scott</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Timpson</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Davey Smith</surname> <given-names>G</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Consortium</surname> <given-names>E-I</given-names></string-name>. <article-title>Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors</article-title>. <source>Eur J Epidemiol.</source> <year>2015</year>;<volume>30</volume>(<issue>7</issue>):<fpage>543</fpage>&#x2013;<lpage>52</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Lippman</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Klein</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Goodman</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Lucia</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Ford</surname> <given-names>LG</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)</article-title>. <source>JAMA.</source> <year>2009</year>;<volume>301</volume>(<issue>1</issue>):<fpage>39</fpage>&#x2013;<lpage>51</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Klein</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>IM</given-names>, <suffix>Jr</suffix></string-name>., <string-name><surname>Tangen</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Crowley</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Lucia</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Goodman</surname> <given-names>PJ</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)</article-title>. <source>JAMA.</source> <year>2011</year>;<volume>306</volume>(<issue>14</issue>):<fpage>1549</fpage>&#x2013;<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="other"><string-name><surname>Schumacher</surname> <given-names>FR</given-names></string-name>, <string-name><surname>Amin Al Olama</surname> <given-names>A</given-names></string-name>, <string-name><surname>Berndt</surname> <given-names>SI</given-names></string-name>, <etal>et al.</etal> <article-title>Prostate cancer meta-analysis of more than 140,000 men identifies 63 novel prostate cancer susceptibility loci</article-title>. <source>Nature Genetics</source>. <year>2017</year>. In Press</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Amos</surname> <given-names>CI</given-names></string-name>, <string-name><surname>Dennis</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Byun</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schumacher</surname> <given-names>FR</given-names></string-name>, <string-name><surname>Gayther</surname> <given-names>SA</given-names></string-name>, <etal>et al.</etal> <article-title>The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers</article-title>. <source>Cancer Epidemiol Biomarkers Prev.</source> <year>2017</year>;<volume>26</volume>(<issue>1</issue>):<fpage>126</fpage>&#x2013;<lpage>35</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Morris</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Voight</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Teslovich</surname> <given-names>TM</given-names></string-name>, <string-name><surname>Ferreira</surname> <given-names>T</given-names></string-name>, <string-name><surname>Segre</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Steinthorsdottir</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal> <article-title>Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes</article-title>. <source>Nat Genet.</source> <year>2012</year>;<volume>44</volume>(<issue>9</issue>):<fpage>981</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>InterAct</surname> <given-names>C</given-names></string-name>, <string-name><surname>Langenberg</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sharp</surname> <given-names>S</given-names></string-name>, <string-name><surname>Forouhi</surname> <given-names>NG</given-names></string-name>, <string-name><surname>Franks</surname> <given-names>PW</given-names></string-name>, <string-name><surname>Schulze</surname> <given-names>MB</given-names></string-name>, <etal>et al.</etal> <article-title>Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study</article-title>. <source>Diabetologia.</source> <year>2011</year>;<volume>54</volume>(<issue>9</issue>):<fpage>2272</fpage>&#x2013;<lpage>82</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="other"><string-name><surname>Collins</surname> <given-names>R</given-names></string-name>. <article-title>What makes UK Biobank special? Lancet</article-title>. <year>2012</year>;<volume>379</volume>(<issue>9822</issue>):<fpage>1173</fpage>&#x2013;<lpage>4</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Lotta</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Scott</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Sharp</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Burgess</surname> <given-names>S</given-names></string-name>, <string-name><surname>Luan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tillin</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis</article-title>. <source>PLoS Med</source>. <year>2016</year>;<volume>13</volume>(<issue>11</issue>):<fpage>e1002179</fpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Cornelis</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Fornage</surname> <given-names>M</given-names></string-name>, <string-name><surname>Foy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Xun</surname> <given-names>P</given-names></string-name>, <string-name><surname>Gladyshev</surname> <given-names>VN</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Genome-wide association study of selenium concentrations</article-title>. <source>Hum Mol Genet</source>. <year>2015</year>;<volume>24</volume>(<issue>5</issue>): <fpage>1469</fpage>&#x2013;<lpage>77</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Evans</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>G</given-names></string-name>, <string-name><surname>Dy</surname> <given-names>V</given-names></string-name>, <string-name><surname>Heath</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Madden</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Kemp</surname> <given-names>JP</given-names></string-name>, <etal>et al.</etal> <article-title>Genome-wide association study identifies loci affecting blood copper, selenium and zinc</article-title>. <source>Hum Mol Genet.</source> <year>2013</year>;<volume>22</volume>(<issue>19</issue>):<fpage>3998</fpage>&#x2013;<lpage>4006</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Mao</surname> <given-names>J</given-names></string-name>, <string-name><surname>Vanderlelie</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Perkins</surname> <given-names>AV</given-names></string-name>, <string-name><surname>Redman</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Ahmadi</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Rayman</surname> <given-names>MP</given-names></string-name>. <article-title>Genetic polymorphisms that affect selenium status and response to selenium supplementation in United Kingdom pregnant women</article-title>. <source>Am J Clin Nutr.</source> <year>2016</year>;<volume>103</volume>(<issue>1</issue>):<fpage>100</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Welter</surname> <given-names>D</given-names></string-name>, <string-name><surname>MacArthur</surname> <given-names>J</given-names></string-name>, <string-name><surname>Morales</surname> <given-names>J</given-names></string-name>, <string-name><surname>Burdett</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>P</given-names></string-name>, <string-name><surname>Junkins</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>The NHGRI GWAS Catalog, a curated resource of SNP-trait associations</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>(<issue>Database issue</issue>):<fpage>D1001</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Burgess</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dudbridge</surname> <given-names>F</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>SG</given-names></string-name>. <article-title>Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods</article-title>. <source>Stat Med.</source> <year>2016</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1880</fpage>&#x2013;<lpage>906</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Svingen</surname> <given-names>GF</given-names></string-name>, <string-name><surname>Schartum-Hansen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Pedersen</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Ueland</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Tell</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Mellgren</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>Prospective Associations of Systemic and Urinary Choline Metabolites with Incident Type 2 Diabetes</article-title>. <source>Clin Chem.</source> <year>2016</year>;<volume>62</volume>(<issue>5</issue>):<fpage>755</fpage>&#x2013;<lpage>65</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Davis</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Uthus</surname> <given-names>EO</given-names></string-name>. <article-title>Dietary folate and selenium affect dimethylhydrazine-induced aberrant crypt formation, global DNA methylation and one-carbon metabolism in rats</article-title>. <source>J Nutr.</source> <year>2003</year>;<volume>133</volume>(<issue>9</issue>):<fpage>2907</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Uthus</surname> <given-names>EO</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>SA</given-names></string-name>. <article-title>Dietary selenium affects homocysteine metabolism differently in Fisher-344 rats and CD-1 mice</article-title>. <source>J Nutr.</source> <year>2007</year>;<volume>137</volume>(<issue>5</issue>):<fpage>1132</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Allen</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Travis</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Appleby</surname> <given-names>PN</given-names></string-name>, <string-name><surname>Albanes</surname> <given-names>D</given-names></string-name>, <string-name><surname>Barnett</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Black</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies</article-title>. <source>J Natl Cancer Inst</source>. <year>2016</year>;<volume>108</volume>(<issue>11</issue>).</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Brooks</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Metter</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>DW</given-names></string-name>, <string-name><surname>Sokoll</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Landis</surname> <given-names>P</given-names></string-name>, <string-name><surname>Nelson</surname> <given-names>WG</given-names></string-name>, <etal>et al.</etal> <article-title>Plasma selenium level before diagnosis and the risk of prostate cancer development</article-title>. <source>J Urol.</source> <year>2001</year>;<volume>166</volume>(<issue>6</issue>):<fpage>2034</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Stampfer</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Giovannucci</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Willett</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Gaziano</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title>A prospective study of plasma selenium levels and prostate cancer risk</article-title>. <source>J Natl Cancer Inst.</source> <year>2004</year>;<volume>96</volume>(<issue>9</issue>):<fpage>696</fpage>&#x2013;<lpage>703</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Nomura</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Stemmermann</surname> <given-names>GN</given-names></string-name>, <string-name><surname>Combs</surname> <given-names>GF</given-names>, <suffix>Jr.</suffix></string-name> <article-title>Serum selenium and subsequent risk of prostate cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev.</source> <year>2000</year>;<volume>9</volume>(<issue>9</issue>):<fpage>883</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>van den Brandt</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Zeegers</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Bode</surname> <given-names>P</given-names></string-name>, <string-name><surname>Goldbohm</surname> <given-names>RA</given-names></string-name>. <article-title>Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study</article-title>. <source>Cancer Epidemiol Biomarkers Prev.</source> <year>2003</year>;<volume>12</volume>(<issue>9</issue>):<fpage>866</fpage>&#x2013;<lpage>71</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Yoshizawa</surname> <given-names>K</given-names></string-name>, <string-name><surname>Willett</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Stampfer</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Spiegelman</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rimm</surname> <given-names>EB</given-names></string-name>, <etal>et al.</etal> <article-title>Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer</article-title>. <source>J Natl Cancer Inst.</source> <year>1998</year>;<volume>90</volume>(<issue>16</issue>):<fpage>1219</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Allen</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Appleby</surname> <given-names>PN</given-names></string-name>, <string-name><surname>Roddam</surname> <given-names>AW</given-names></string-name>, <string-name><surname>Tjonneland</surname> <given-names>A</given-names></string-name>, <string-name><surname>Johnsen</surname> <given-names>NF</given-names></string-name>, <string-name><surname>Overvad</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)</article-title>. <source>Am J Clin Nutr.</source> <year>2008</year>;<volume>88</volume>(<issue>6</issue>):<fpage>1567</fpage>&#x2013;<lpage>75</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Helzlsouer</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>HY</given-names></string-name>, <string-name><surname>Alberg</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Hoffman</surname> <given-names>S</given-names></string-name>, <string-name><surname>Burke</surname> <given-names>A</given-names></string-name>, <string-name><surname>Norkus</surname> <given-names>EP</given-names></string-name>, <etal>et al.</etal> <article-title>Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer</article-title>. <source>J Natl Cancer Inst.</source> <year>2000</year>;<volume>92</volume>(<issue>24</issue>):<fpage>2018</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Ference</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Yoo</surname> <given-names>W</given-names></string-name>, <string-name><surname>Alesh</surname> <given-names>I</given-names></string-name>, <string-name><surname>Mahajan</surname> <given-names>N</given-names></string-name>, <string-name><surname>Mirowska</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Mewada</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis</article-title>. <source>J Am Coll Cardiol.</source> <year>2012</year>;<volume>60</volume>(<issue>25</issue>):<fpage>2631</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Baigent</surname> <given-names>C</given-names></string-name>, <string-name><surname>Keech</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kearney</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Blackwell</surname> <given-names>L</given-names></string-name>, <string-name><surname>Buck</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pollicino</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins</article-title>. <source>Lancet.</source> <year>2005</year>;<volume>366</volume>(<issue>9493</issue>):<fpage>1267</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Swerdlow</surname> <given-names>DI</given-names></string-name>, <string-name><surname>Preiss</surname> <given-names>D</given-names></string-name>, <string-name><surname>Kuchenbaecker</surname> <given-names>KB</given-names></string-name>, <string-name><surname>Holmes</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Engmann</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials</article-title>. <source>Lancet.</source> <year>2015</year>;<volume>385</volume>(<issue>9965</issue>):<fpage>351</fpage>&#x2013;<lpage>61</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Sattar</surname> <given-names>N</given-names></string-name>, <string-name><surname>Preiss</surname> <given-names>D</given-names></string-name>, <string-name><surname>Murray</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Welsh</surname> <given-names>P</given-names></string-name>, <string-name><surname>Buckley</surname> <given-names>BM</given-names></string-name>, <string-name><surname>de Craen</surname> <given-names>AJ</given-names></string-name>, <etal>et al.</etal> <article-title>Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials</article-title>. <source>Lancet.</source> <year>2010</year>;<volume>375</volume>(<issue>9716</issue>):<fpage>735</fpage>&#x2013;<lpage>42</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Holmes</surname> <given-names>MV</given-names></string-name>, <string-name><surname>Simon</surname> <given-names>T</given-names></string-name>, <string-name><surname>Exeter</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Folkersen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Asselbergs</surname> <given-names>FW</given-names></string-name>, <string-name><surname>Guardiola</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study</article-title>. <source>J Am Coll Cardiol.</source> <year>2013</year>;<volume>62</volume>(<issue>21</issue>):<fpage>1966</fpage>&#x2013;<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Millwood</surname> <given-names>IY</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Walters</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Clarke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Waterworth</surname> <given-names>D</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults</article-title>. <source>Int J Epidemiol.</source> <year>2016</year>;<volume>45</volume>(<issue>5</issue>):<fpage>1588</fpage>&#x2013;<lpage>99</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="other"><article-title>Clinical Study Report for Study AN-CVD2233</article-title>. <source>Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects with Acute Coronary Syndromes</source>.; <year>2012</year>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Voight</surname> <given-names>BF</given-names></string-name>, <string-name><surname>Peloso</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Orho-Melander</surname> <given-names>M</given-names></string-name>, <string-name><surname>Frikke-Schmidt</surname> <given-names>R</given-names></string-name>, <string-name><surname>Barbalic</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jensen</surname> <given-names>MK</given-names></string-name>, <etal>et al.</etal> <article-title>Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study</article-title>. <source>Lancet.</source> <year>2012</year>;<volume>380</volume>(<issue>9841</issue>):<fpage>572</fpage>&#x2013;<lpage>80</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Barter</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Caulfield</surname> <given-names>M</given-names></string-name>, <string-name><surname>Eriksson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Grundy</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Kastelein</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Komajda</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Effects of torcetrapib in patients at high risk for coronary events</article-title>. <source>N Engl J Med.</source> <year>2007</year>;<volume>357</volume>(<issue>21</issue>):<fpage>2109</fpage>&#x2013;<lpage>22</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Group</surname> <given-names>HTC</given-names></string-name>, <string-name><surname>Landray</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Haynes</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hopewell</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Parish</surname> <given-names>S</given-names></string-name>, <string-name><surname>Aung</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Effects of extended-release niacin with laropiprant in high-risk patients</article-title>. <source>N Engl J Med.</source> <year>2014</year>;<volume>371</volume>(<issue>3</issue>):<fpage>203</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Group</surname> <given-names>AS</given-names></string-name>, <string-name><surname>Ginsberg</surname> <given-names>HN</given-names></string-name>, <string-name><surname>Elam</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Lovato</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Crouse</surname> <given-names>JR</given-names>, <suffix>3rd</suffix></string-name>, <string-name><surname>Leiter</surname> <given-names>LA</given-names></string-name>, <etal>et al.</etal> <article-title>Effects of combination lipid therapy in type 2 diabetes mellitus</article-title>. <source>N Engl J Med.</source> <year>2010</year>;<volume>362</volume>(<issue>17</issue>):<fpage>1563</fpage>&#x2013;<lpage>74</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>